Agilent Technologies Life Sciences and Diagnostics Markets — Depreciation increased by 13.0% to $26.00M in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 13.0%, from $23.00M to $26.00M.
Increasing depreciation may signal significant recent capital investment in new equipment, while stable levels indicate a consistent asset base.
This is the systematic allocation of the cost of tangible assets, such as manufacturing equipment and laboratory facilit...
Standard non-cash expense metric for capital-intensive businesses.
a_segment_life_sciences_and_diagnostics_markets_depreciation| Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Value | $15.00M | $15.00M | $15.00M | $15.00M | $18.00M | $18.00M | $18.00M | $18.00M | $23.00M | $26.00M |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | +20.0% | +0.0% | +0.0% | +0.0% | +27.8% | +13.0% |
| YoY Change | — | — | — | — | +20.0% | +20.0% | +20.0% | +20.0% | +27.8% | +13.0% |